A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis

by Laura Callan, MD, MASc, Glenn Bauman, MD, Jeff Chen, PhD, Michael Lock, MD, Tracy Sexton, MD, PhD, David D'Souza, MD, George Rodrigues, MD, PhD
Published 2019-10-01